ANDA 205300, held by Teva Pharms USA. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 205300 (Atorvastatin Calcium), held by Teva Pharms USA, was first approved by FDA on Mar 27, 2017, with 7 approved supplements and 0 published complete response letters.
Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2017 | Original application | Approved |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Mar 11, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 11, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 11, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 11, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 11, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 11, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 11, 2025 | Supplement 23Labeling · Standard review | Approved | None posted |
| Mar 27, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters